Show simple item record

dc.contributor.authorChoo, Peter W
dc.contributor.authorRand, Cynthia S
dc.contributor.authorInui, Thomas S
dc.contributor.authorLee, Mei-Ling Ting
dc.contributor.authorCanning, Claire
dc.contributor.authorPlatt, Richard
dc.date.accessioned2011-06-30T18:20:11Z
dc.date.issued2001
dc.identifier.citationChoo, Peter W., Cynthia S. Rand, Thomas S. Inui, Mei-Ling Ting Lee, Claire Canning, and Richard Platt. 2001. A cohort study of possible risk factors for over-reporting of antihypertensive adherence. BMC Cardiovascular Disorders 1:6.en_US
dc.identifier.issn1471-2261en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:4930640
dc.description.abstractBackground: The identification of poor medicinal adherence is difficult because direct observation of medication use is usually impractical. Up to 50% of individuals on chronic therapies may not be taking their medication as prescribed. This study is one of the first to explore possible risk factors for over-reporting of antihypertensive adherence using electronic medication monitoring. Methods: The adherence of 286 individuals on single-drug antihypertensive therapy in a large managed care organization was electronically monitored for approximately three months. Questionnaires on socioeconomic background, adherence to therapy, health beliefs, and social support before and after adherence monitoring were completed. Over-reporting of antihypertensive adherence was assessed by comparing the self-reported frequency of noncompliance with that determined from electronic dosing records. Risk factors for overreporting were identified by contingency table analysis and step-wise logistic regression. Results: Although only 21% of participants acknowledged missing doses on one or more days per week, electronic monitoring documented nonadherence at this or a higher level in 42% of participants. The following variables were associated with over-reporting: >1 versus 1 daily dose (OR = 2.58; 95% CI = 1.50–4.41; p = .0006), lower perceived health risk from nonadherence (OR = 1.35; 95% CI = 1.10–1.64; p = .0035), and annual household income of <$15,000 versus >$30,000 (OR = 2.64; 95% CI = 1.13–6.18; p = .025). Conclusions: Over-reporting of adherence may be affected by factors related to dosing frequency, health beliefs and socioeconomic status. This topic deserves further investigation in other patient populations to elucidate possible underlying behavioral explanations.en_US
dc.language.isoen_USen_US
dc.publisherBioMed Centralen_US
dc.relation.isversionofdoi:10.1186/1471-2261-1-6en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC64641/pdf/en_US
dc.relation.hasversionhttp://www.biomedcentral.com/1471-2261/1/6en_US
dash.licenseLAA
dc.titleA Cohort Study of Possible Risk Factors for Over-Reporting of Antihypertensive Adherenceen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalBMC Cardiovascular Disordersen_US
dash.depositing.authorPlatt, Richard
dc.date.available2011-06-30T18:20:11Z
dash.affiliation.otherHMS^Population Medicineen_US
dc.identifier.doi10.1186/1471-2261-1-6*
dash.contributor.affiliatedCanning, Claire
dash.contributor.affiliatedPlatt, Richard


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record